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Background: Ipilimumab induces long-lasting clinical responses in a minority of patients with metastatic
melanoma. To better understand the mechanism(s) of action and to identify novel biomarkers associated
with the clinical benefit and toxicity of ipilimumab, baseline characteristics and changes in CD4+ and CD8+
T cells from melanoma patients receiving ipilimumab were characterized by gene profiling and flow
cytometry.
Methods: Microarray analysis of flow-cytometry purified CD4+ and CD8+ T cells was employed to assess
gene profiling changes induced by ipilimumab. Selected molecules were further investigated by flow
cytometry on pre, 3-month and 6-month post-treatment specimens.
Results: Ipilimumab up-regulated Ki67 and ICOS on CD4+ and CD8+ cells at both 3- and 6-month post ipilimumab
(p≤ 0.001), decreased CCR7 and CD25 on CD8+ at 3-month post ipilimumab (p≤ 0.02), and increased Gata3 in CD4+
and CD8+ cells at 6-month post ipilimumab (p≤ 0.001). Increased EOMES+CD8+, GranzymeB+EOMES+CD8+ and decreased
Ki67+EOMES+CD4+ T cells at 6 months were significantly associated with relapse (all p≤ 0.03). Decreased Ki67+CD8+ T
cells were significantly associated with the development of irAE (p = 0.02). At baseline, low Ki67+EOMES+CD8+ T cells were
associated with relapse (p≤ 0.001), and low Ki67+EOMES+CD4+ T cells were associated with irAE (p≤ 0.008).
Conclusions: Up-regulation of proliferation and activation signals in CD4+ and CD8+ T cells were pharmacodynamic
markers for ipilimumab. Ki67+EOMES+CD8+ and Ki67+EOMES+CD4+T cells at baseline merit further testing as biomarkers
associated with outcome and irAEs, respectively.
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T cells play a pivotal role in the development of immune
tolerance to self, autoimmunity, and anti-tumor
responses. Cytotoxic T Lymphocyte-Associated antigen
4 (CTLA-4) is a surface receptor on T lymphocytes that
down-regulates pathways of T-cell activation [1], serving
as an immune check point molecule. It is expressed
intracellularly in resting T cells, and is transported to the
T cell surface after activation of the T cell receptor
(TCR). TCR engagement leads to tyrosine phosphoryl-
ation of CTLA-4 at position 164 (164Y) via the SRC kin-
ase and releases it from AP50, resulting in its surface* Correspondence: Wenshi.wang@moffitt.org
1Department of Cutaneous Oncology and the Donald A. Adam
Comprehensive Melanoma Research Center, H. Lee Moffitt Cancer Center,
Tampa, FL, USA
Full list of author information is available at the end of the article
© 2012 Wang et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orexpression within 48 hours of T cell activation, leading
to T cell tolerance and anergy. CTLA-4 expression is
associated with decreased proliferation with cell cycle
arrest at the G1-S interface and diminished cytokine
secretion [2, 3]. It decreases cell proliferation through
the inhibition of mitogen-activated (MAP) kinases but
promotes T cell survival through the binding of
phosphoinositol-3 kinase and activating protein kinase
B (PKB/AKT) resulting in T cell anergy and tolerance
without the death of T cells [4]. CTLA-4 signals sup-
press both CD4+ and CD8+ T cell responses via a
tyrosine-based inhibitory motif [5, 6].
CTLA-4 blockade has antitumor activity in mice, and
important effects on the breaking of tolerance [6-10]. In
experiments with B16 melanoma, a therapeutic effect
induced by CTLA-4 blockade with a vaccine wastd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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suggesting that expansion of T cells recognizing melano-
cyte lineage antigens was associated with its therapeutic
effect. Several autoimmune diseases were associated with
the single nucleotide polymorphisms in the CTLA-4
gene, including hypothyroidism and type 1 diabetes [11].
In CTLA-4 -/- knockout mice, expansion of lymphocytes
with diffuse lymphadenopathy and lymphoid infiltration
of different organs occurs, consistent with a generalized
expansion of T cells [12]. Similarly, both preclinical and
clinical data indicate that CTLA-4 blockade results in
activation and expansion of the total CD4+ and CD8+ ef-
fector T cells [13], and the breaking of self-tolerance has
been shown in patients, as evidenced by the occurrence
of immune-related adverse events (irAEs) observed with
two different CTLA-4 antibodies, ipilimumab (Bristol
Myers Squibb, Princeton, NJ) [14] and tremelimumab
(Pfizer, New York, NY) [15].
Ipilimumab is a fully human CTLA-4 blocking IgG1
monoclonal antibody which induces long-lasting clinical
responses in a minority of patients with metastatic melan-
oma [16-21]. Ipilimumab with or without a gp100 peptide
vaccine, compared with gp100 vaccine alone, improved
overall survival (OS) in patients with previously treated
metastatic melanoma [22]. Ipilimumab when combined
with dacarbazine improved overall survival in previously
untreated patients compared to dacarbazine alone [23].
These were the first randomized Phase III trials to demon-
strate a significant survival impact for patients with meta-
static melanoma, yet few studies have shed light on its
anti-tumor mechanism, or documented pharmacodynamic
(PD) markers of the impact of ipilimumab. An increase in
the absolute lymphocyte count (ALC) after 2 or 3 doses of
the drug at weeks 4 and 7 has been documented [24], and
may correlate with an improved outcome; increased CD4+
HLA-DR+ T cells have been shown in several studies to
occur after ipilimumab therapy [25, 26]; in several small
cohort studies of brief duration, ipilimumab treatment
increased the frequency of CD4+ICOShi T cells in tumors
and in the circulation, and it also induced antibody
reactivity against the cancer-testis antigen NY-ESO-1
[27, 28]. CTLA-4 abrogating antibodies do not impact on
vaccine-specific immune responses [29] and even when
administered with a peptide vaccine, tumor antigen-
specific responses were only modestly increased [29, 30].
Recall responses to viral and other antigens were not
altered by ipilimumab. In patients receiving another
CTLA-4 abrogating antibody, tremelimumab, the ratio of
intratumoral T cells to FoxP3 positive T regulatory cells
was increased after treatment only in regressing lesions
[30], suggesting a therapeutic impact of CTLA-4 abroga-
tion on T cells infiltrating the tumor. The same investiga-
tors also demonstrated that peripheral blood Th17 cells
were induced by tremelimumab [31], and that certainsignaling pathways downstream of the TCR and cytokine
receptor were also influenced by CTLA-4 blockade, such
as increased pp38, pSTAT1 and pSTAT3, and decreased
pLck, pERK1/2 and pSTAT5 levels [32]. CTLA-4 blockade
also induced cell proliferation in the spleen, a secondary
lymphoid organ, shown by molecular imaging with the
PET probe 18 F-FLT [33]. Those investigators also
reported significantly increased intratumoral CD4+ and
mostly CD8+ T cell infiltration, with increased HLA-DR
and CD45RO double positive cells in post tremelimumab
biopsies [34] and increased expression of FoxP3.
To date, the molecular basis and mechanisms of action
of ipilimumab have not been documented systematically
in vivo. There is a critical need for biomarkers of the
effects of ipilimumab as well as potential predictive mar-
kers for clinical outcome and induction of irAE. There-
fore, in the current study we investigated the effects of
ipilimumab on the gene expression profile of CD4+ and
CD8+ T cells by microarray analysis when it was admi-
nistered as adjuvant therapy to 12 patients in a trial for
patients with high risk resected melanoma. We further
clarified the immunophenotypic changes induced by ipi-
limumab on CD4+ and CD8+ T cells by a flow cytometry
study of an expanded group of 37 patients and identified
potential predictive biomarkers from pre-treatment spe-
cimens of 55 patients. Our studies provide evidence of




Between June 2004 and December 2008, 75 patients (39 at
the University of Southern California, Norris Cancer Cen-
ter and 36 at the Moffitt Cancer Center) with resected
stage IIIC/IV melanoma received ipilimumab with or
without a peptide vaccine. The demographic and clinic
outcomes of the patients in the current study are shown
in Table 1, which have been previously reported [26]
with updated follow-up: three additional patients died
(R DOD); one additional patient relapsed and was resected
with no evidence of disease (R NED) instead of being
NED. Toxicity was assessed by the National Cancer Insti-
tute Common Terminology Criteria for Adverse Events,
version 3.0. The protocol was approved by the University
of Southern California/Los Angeles County and University
of South Florida Institutional Review Boards, and all
patients provided written informed consent.
PBMC collection, preparation and T cells purification
Apheresis with exchange of 5 to 7 liters was performed
within 1 week before and 6 months after the initiation of
therapy, after four doses of ipilimumab. Heparinized
blood was collected after 2 doses of ipilimumab,
3 months after the initiation of therapy. PBMC were
Table 1 Demographics and treatment related variables of
all patients in this study (n = 55)
Variable Level n (%)
gender F 21 (38.2)
M 34 (61.8)
stage IIIc 24 (43.6)
IV 31 (56.4)
HLA A2 A2+ 34 (61.8)
A2- 21 (38.2)
dosage 10 mg/kg 40 (72.7)
3 mg/kg 15 (27.3)
irAE N 31 (56.4)
Y 24 (43.6)
Outcome NED 35 (63.6)
Relapse 20 (36.4)
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treatment specimens by Lymphoprep (Greiner Bio-One,
Longwood, FL) density gradient centrifugation. PBMC
were counted, then frozen in 90% heat inactivated
human AB serum (HS, Omega Scientific, Tarzana, CA)
and 10% dimethyl sulfoxide (DMSO) (Sigma, St Louis,
MO) and stored in secured liquid nitrogen freezers
at −168°C until use.
Cryopreserved pre- and 6-month post-treatment
PBMC from each patient were thawed immediately into
pre-warmed AIM-V media (Invitrogen Corporation,
Grand Island, NY) supplemented with 5% HS. For
microarray analysis, PBMCs were sorted as follows: cells
were stained with CD3-FITC (BD Bioscience, San Diego,
CA), CD4-PE (BD Bioscience), CD8-APC (BD Bio-
science) for 30 min at 4°C. After extensive washing,
PBMCs were stained with DAPI nucleic acid dye (Invi-
trogen) to exclude dead and dying cells. After washing
with staining buffer (PBS + 0.5% HS), PBMC were re-
suspended in staining buffer for flow cytometry sorting.
CD3+CD4+CD8-, CD3+CD8+CD4- T cells cell popula-
tions were collected by Aria (BD Bioscience, San Jose,
CA). The purity of the sorted specific cell populations
were consistently ≥ 99%.
Microarray analysis
The sorted cells were pelleted and re-suspended in a RLT
lysis buffer (Qiagen Science, Valencia, CA), and delivered
to the Microarray Core (Moffitt Cancer Center, Tampa,
FL) for expression array analysis. RNA from the sorted cell
populations were DNase-treated and extracted using the
Qiagen RNeasy mini-prep according to the manufacturer’s
protocol (Qiagen). The Nugen Message Amp Premier kit
was used to amplify 100 nanograms of total RNA (Nugen
Technologies, San Carlos, CA). Briefly, the extracted poly-(A) RNA was specifically converted to cDNA, amplified
and labeled with biotin following the procedure initially
described by Van Gelder et al. [35]. Biotin-labeled cDNA
was hybridized onto Affymetrix U133 Plus 2.0 microar-
rays. Microarray data were then analyzed using Affymetrix
Expression Console. Gene detect calls were obtained using
the Affymetrix MAS5 algorithm [36] to filter genes that
are not expressed across the board and express value or
signal intensity was calculated by the robust multi-array
analysis method (RMA) developed by Irizarry et al [37].
Differential gene expressions were then assessed using
Student’s t-test and false discovery rate (FDR) was esti-
mated [38].Surface and intracellular staining
For cell surface staining, 1–2 × 106 PBMC in 100 μl PBS
were stained with the Aqua-live/dead fixable dye (Invitro-
gen) at 4°C for 30 min. After washing, PBMC were stained
with fluorochrome-conjugated antibodies against cell sur-
face markers prepared as a master-mix-solution for 30 min
at 4°C. The antibodies for surface markers were purchased
from BD Bioscience unless otherwise specified: CD3-
AlexFluor 700, CD4-PECy7, CD8-PERCPCy5.5, ICOS-PE,
CCR7-FITC (R&D Systems, Minneapolis, MN), CCR7-PE
(R & D Systems), CXCR3-FITC (R & D Systems), CD109-
PE, CD45RA-FITC, CD28-APC (eBioscience, San Diego,
CA), IL-7R-APC (R & D system), CD25-FITC, TGFβR3-PE
(R & D Systems) and MIC-A-APC (R & D Systems). The
fluorescent-minus-one and isotype control were included
in each experiment in order to appropriately set the gates.
A total of 300,000 live single lymphocytes were acquired
on a LSR II flow cytometer (BD Bioscience). Analysis gates
were set on single live lymphocytes defined by scatter char-
acteristics and Aqua negative staining. First, we gated lym-
phocytes by forward and side scatter, then gated on single
cells by forward and sideward width and height. We
observed single live lymphocytes by gating on aqua nega-
tively stained single lymphocytes (Additional file 1: Figure
S1 –row 1). In the whole study, we observed the biomar-
kers on/in CD4+ (Additional file 1: Figure S1-row 2, 3) and
CD8+ T cells (Additional file 1: Figure S1-row 4, 5). The
gating strategies for the biomarkers presented in this paper
are shown in Additional file 1: Figure S1.
For intracellular staining, 2–3 × 106 PBMC in 100 μl
staining buffer were treated as above, then fixed with a
freshly prepared Fixation/Permeabilization working solu-
tion (eBioscience) at 4°C for 30 min. After wash with
permeabilization buffer (eBioscience), the cells were
stained with intracellular markers: Ki67-FITC (Abcam,
Cambridge, MA), EOMESodermin (EOMES)-Alex Fluor
647 (eBioscience), granzyme B-FITC, perforin-PE, FoxP3 –
APC (eBioscience), GATA 3-Alex Fluor 647 (eBioscience),
cleaved caspase III-PE for 30 min at 4°C. Cells were then
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staining buffer for flow cytometry acquistion.
For the standardization of flow cytometry assays and
the consistency of daily performance, a normal PBMC
sample was stained and run on flow cytometry in paral-
lel with the subject samples and Spherotech rainbow
fluorescent particles (Spherotech, Inc, Lake Forest, IL)
were run before running samples for alignment of the
optical system of the flow cytometer in each channel.
Flow cytometry analysis
Flow cytometry data were analyzed using Flowjo soft-
ware (Version 9.0.2, Tree Star, Inc., Asland, OR). The
mean fluorescence intensity (MFI) and percent of posi-
tive expression (%) of each marker were measured for
CD4+ and CD8+ T cells.
Statistical analysis
Descriptive summary statistics, e.g., frequency and % for
discrete variables and mean (standard deviation: SD),
interquartiles and median (range) for continuous variables,
were reported as appropriate. Both absolute change and
fold change, i.e., post-pre and (post-pre)/pre, were ana-
lyzed to account for a potentially better normalization
under the log scale for the immunological biomarkers
under investigation. Median changes and interquartiles
were reported for the biomarker change variables due to
concerns on sometimes small sample sizes and the under-
lying normality assumption required for a valid confidence
interval. Wilcoxon signed-rank test was used to test
whether changes in immunological biomarker expression
levels between pre-, to 3- and 6-month post-ipilimumab
were statistically significant. Both point estimates and their
confidence intervals (CIs) were provided for parameters of
interest, e.g., odds ratio (OR). Confidence intervals were
set at the 95% level. Univariate logistic regression models
were employed to explore the effects of baseline and abso-
lute change as well as fold change of each biomarker on
disease outcome (Relapsed vs. NED) and irAE (Yes vs.
No). The CI for OR based on the univariate logistic re-
gression model results was calculated for an increment
that equals to one half of the interquartile range of the
corresponding change variable for each of the biomarkers.
Baseline biomarkers were also dichotomized using their
respective medians and then correlated with the disease
outcome (Relapsed vs. NED) and irAE (Yes vs. No) using
the 2x2 contingency table approach. The resulting ORs,
their CIs and Fisher test p-values were reported. The
Kaplan-Meier product-limit analysis and log-rank test
were employed to address the question of whether
relapse-free survival was associated with any of the dichot-
omized biomarkers at baseline. A p-value of ≤ 0.05 was
considered statistically significant and no multiple com-
parison adjustments were made in this exploratorybiomarker study except for the gene microarray part of
the data analyses. All statistical analyses were performed
using SAS version 9.
Results
Gene expression of CD4+ and CD8+ T cells induced by
ipilimumab
To assess the effect of ipilimumab on overall gene expres-
sion in CD4+ and CD8+ T cells in vivo, microarray analysis
was conducted on T cells purified by flow cytometry from
PBMCs collected from 12 resected melanoma patients pre-
and 6-month post-ipilimumab treatment (Additional file 1:
Table S1). Differentially expressed genes were selected with
a paired student T-test p-value of 0.03 or less (p ≤ 0.03)
and a fold change of the group mean of 1.2 or greater
(≥ 1.2) or 0.8 or less (≤ 0.8). Table 2a and 2b show some
immune-related genes from the top differentially expressed
genes in CD4+ and CD8+ T cells, respectively, after ipilimu-
mab treatment. The genes were categorized by biological
process and/or gene function: cell cycle, cytokine-related,
chemokine-related, T cell activation and proliferation sig-
nal-related, survival and apoptotic signal-related, kinase-
related and heat shock protein family-related genes. It is
worth noting that the genes most impacted by ipilimumab
were cell cycle related in both CD4+ and CD8+ T cells. Ipi-
limumab appeared to release the arrested cell cycle in CD4
+ and CD8+ T cells as evidenced by highly significant and
consistent up-regulation of CDC2 (Table 2a and 2b), and
other cell cycle related genes (data not shown).
Pharmacodynamic effects of ipilimumab on T cells
To verify changes in selected molecules from the micro-
array analysis and further investigate the mechanism of ac-
tion of ipilimumab, a flow cytometry study was undertaken
with the pre-, 3-month and 6-month post-ipilimumab
PBMCs from expanded groups of 55, 25 and 37 patients,
respectively (Table 2, Additional file 1: Table S1b and S1c),
overlapping the microarray cohort of 12 but limited to all
patients with sufficient PBMC available for analysis. In
addition to the selected immunological biomarkers, we also
measured CD4+ and CD8+ T cell effector-memory/naive
phenotypes. We observed that naïve CD4+ and CD8+ T
cells (CCR7+CD45RA+) were significantly reduced 6months
after ipilimumab, with a corresponding significant increase
in CD8+ central memory and CD4+ effector memory Tcells
(data not shown). We report below biomarkers that signifi-
cantly changed both in absolute value and by fold change
for % (positivity) with p ≤ 0.02 by Wilcoxon.
Increased Ki67 expression in, and ICOS on CD4+ and CD8+
T cells 3 and 6 months after ipilimumab
The Ki-67 protein (also known as MKI67) is a cellular
marker for proliferation [39] and cell cycling [40] and is
an indicator of the growth fraction of a given cell
Table 2 Microarray data for immune related genes from CD4+ T cells (Table 2a) and CD8+ T cells (Table 2b) with fold
increases over baseline control samples, p-values for the differences indicated, FDR for the false discovery rate, and
the mean ± SD of pre and post samples for the gene expression ranges
Gene symbol Gene name Fold-change p-value FDR Pre-Mean ±SD Post-Mean ±SD
a. Genes impacted by ipilimumab in CD4+ T cells
Cell cycle related
CDC2 cell division cycle 2, G1 to S and G2 to M 1.98 0.009 0.0409 18.61 ± 4.41 36.92 ± 21.36
2.78 0.0142 0.0432 66.68 ± 59.31 185.59 ± 185.36
TYMS thymidylate synthetase 2.77 0.0075 0.0408 129.75 ± 58.10 358.99 ± 254.47
CCNB2 cyclin B2 2.08 0.0142 0.0434 28.17 ± 11.75 58.49 ± 45.13
CDK7 cyclin-dependent kinase 7 1.26 0.0074 0.0408 214.08 ± 75.01 270.13 ± 106.34
Cytokines-related
PGDS prostaglandin D2 synthase, hematopoietic 2.2 0.0024 0.0393 14.20 ± 5.42 31.30 ± 14.57
1.51 0.0048 0.04044 489.68 ± 470.87 740.39 ± 581.83
TGFBR3 transforming growth factor β RIII 1.39 0.0111 0.0411 505.71 ± 304.47 701.22 ± 246.45
IFNy interferon, γ 1.46 0.0255 0.0751 138.35 ± 104.72 201.55 ± 120.78
IL-7 interleukin 7 1.28 0.0169 0.0511 15.43 ± 10.42 19.73 ± 8.89
STAT1 signal transducer and activator of transcription 1 1.28 0.0081 0.0409 1141.96 ± 330.11 1460.67 ± 577.64
SCYE1 small inducible cytokine subfamily E, member 1 1.27 0.0103 0.041 278.24 ± 100.74 352.82 ± 149.81
0.80 0.0061 0.0406 5219.38 ± 1457.55 4291.38 ± 1772.32
IL-7R interleukin 7 receptor 0.74 0.0011 0.0375 3309.89 ± 1296.32 2467.81 ± 1094.22
IL-2Rα interleukin 2 receptor, α 0.69 0.01811 0.0544 113.56 ± 58.89 79.12 ± 39.28
IL-15 interleukin 15 0.74 0.0032 0.0398 54.76 ± 39.59 40.63 ± 31.09
TNFSF8 tumor necrosis factor superfamily, member 8 0.73 0.0202 0.0605 248.08 ± 148.25 181.53 ± 92.03
Chemokines-related
ITGB1 integrin, β1 (antigen CD29) 1.29 0.0055 0.0405 1449.91 ± 772.02 1867.82 ± 802.10
1.20 0.0012 0.0375 396.68 ± 336.59 476.25 ± 376.51
CXCR3 chemokine receptor 3 1.29 0.0286 0.0825 47.04 ± 23.35 60.53 ± 33.18
CXCR7 chemokine receptor 7 0.75 0.0205 0.0614 83.62 ± 25.83 63.45 ± 25.78
ITGA6 integrin, α6 0.72 0.0211 0.063 1166.8 ± 1046.57 837.4 ± 796.19
Activation, proliferation and differentiation-related
MKI67 antigen identified by monoclonal antibody Ki-67 1.98 0.0165 0.0498 41.58 ± 22.80 82.16 ± 62.67
1.69 0.0104 0.0410 19.37 ± 9.50 32.73 ± 20.37
ICOS inducible T-cell costimulator 1.49 0.0011 0.0375 587.76 ± 294.69 874.26 ± 397.84
GATA3 GATA binding protein 3 1.43 0.0124 0.042 284.77 ± 189.82 406.03 ± 268.34
1.37 0.0023 0.0392 163.55 ± 83.74 224.53 ± 114.73
CTLA-4 cytotoxic T-lymphocyte-associated protein 4 1.37 0.0249 0.0734 511.58 ± 260.28 700.23 ± 359.54
MICA MHC class I polypeptide-related sequence A 0.7 0.0015 0.0379 120.33 ± 67.61 84.36 ± 51.72
BCL family-related
Bcl3 B-cell CLL/lymphoma 3 1.56 0.0036 0.0400 199.55 ± 112.65 311.36 ± 120.66
BAK1 Bcl2-antagonist/killer 1 1.26 2.00E-04 0.0365 130.50 ± 27.61 164.92 ± 33.45
1.24 0.0067 0.0407 314.36 ± 77.54 388.54 ± 79.60
Bcl2L11 Bcl2-like 11 1.21 0.0369 0.1053 442.48 ± 299.18 536.88 ± 388.57
BCLAF1 Bcl2-associated transcription factor 1 1.21 0.0234 0.0695 61.14 ± 14.91 73.89 ± 26.64
0.72 0.0158 0.0479 189.15 ± 81.00 137.91 ± 40.11
Bcl2 B-cell CLL/lymphoma 2 0.63 0.0050 0.0404 427.68 ± 327.43 272.97 ± 207.62
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Table 2 Microarray data for immune related genes from CD4+ T cells (Table 2a) and CD8+ T cells (Table 2b) with fold
increases over baseline control samples, p-values for the differences indicated, FDR for the false discovery rate, and
the mean ± SD of pre and post samples for the gene expression ranges (Continued)
Apoptosis, MAP kinase and protein kinase-related
ANXA5 annexin 5 1.32 0.0271 0.0794 599.68 ± 269.08 793.89 ± 425.06
MAPK6 mitogen-activated protein kinase 6 1.31 0.0261 0.0768 209.49 ± 142.30 273.63 ± 202.36
PPP1CC protein phosphatase 1, catalytic subunit, γ isoform 1.23 0.0152 0.0462 998.56 ± 432.59 1225.87 ± 571.01
CASP7 caspase 7, apoptosis-related cysteine peptidase 1.22 0.0145 0.0441 141.11 ± 41.72 171.83 ± 48.77
MAP2K6 mitogen-activated protein kinase kinase kinase 6 0.77 0.0105 0.0410 77.3 ± 41.24 59.77 ± 33.17
ANXA11 annexin 11 0.75 0.0003 0.0368 93.23 ± 20.45 70.21 ± 31.98
ATF7 activating transcription factor 7 0.75 0.0252 0.0743 170.44 ± 120.64 128.30 ± 107.21
MAP4K4 mitogen-activated protein kinase kinase kinase 4 0.63 0.0095 0.041 137.49 ± 51.60 86.97 ± 29.96
b. Genes impacted by ipilimumab in CD8+ T cells
Cell cycle-related
CDC2 cell division cycle 2, G1 to S and G2 to M 1.81 0.03 0.0897 18.37 ± 6.09 33.23 ± 21.15
CDCA7 Cell division cycle associated 7 1.67 0.0113 0.0647 87.63 ± 93.37 146.50 ± 111.23
Cytokines-related
TNFSF4 tumor necrosis factor superfamily, member 4 0.58 0.0082 0.0647 40.88 ± 27.10 23.93 ± 14.71
Chemokines-related
ITGAV integrin, αV (antigen CD51) 0.80 5.00E-04 0.0647 114.65 ± 54.10 91.78 ± 42.91
Activation, Differentiation and Interaction-related
HLA-DRB4 major histocompatibility complex, class II, DR β4 1.4 0.0163 0.0647 28.04 ± 26.29 39.18 ± 37.40
1.39 0.0100 0.0647 178.84 ± 104.07 248.93 ± 148.36
GATA3 GATA binding protein 3 1.35 0.0026 0.0647 139.84 ± 44.14 188.83 ± 75.51
HLA-DRA major histocompatibility complex, class II, DR α 1.38 0.0193 0.0647 540.53 ± 402.57 745.47 ± 350.32
CD6 CD6 molecule (CD166 receptor) 1.32 0.0248 0.0754 179.47 ± 95.79 236.58 ± 157.76
CD5 CD5 molecule 1.22 0.0181 0.0647 103.58 ± 38.21 126.47 ± 45.17
EOMES Eomesodermin 0.69 0.0292 0.0877 1063.26 ± 642.42 738.05 ± 445.38
Apoptosis, MAP Kinases-related
TIAM1 T-cell lymphoma invasion and metastasis 1 1.68 0.0105 0.0647 83.63 ± 67.00 140.61 ± 116.68
ANXA5 annexin 5 1.31 0.0114 0.0647 576.93 ± 278.33 747.53 ± 316.78
API5 apoptosis inhibitor 5 1.24 0.0088 0.0647 187.92 ± 118.48 233.04 ± 151.93
Increases of greater than 1.2 fold and decreases of 0.8 fold or less are shown. Multiple values refer to different expressed sequence tags from the same gene.
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the % of Ki67+/CD4+ and Ki67+/CD8+ T cells were sig-
nificantly increased in both 3-month and 6-month post-
treatment PBMCs with p ≤ 0.0009 for all by Wilcoxon
test and a median fold-increase ranging from 0.54 to
1.50. The increase in Ki67 +/CD4+ T cells was higher at
3-month post ipilimumab treatment than at 6-month
post treatment, but the increase of Ki67+/CD8+ T cells
was higher at 6-month post ipilimumab than at 3-month
post ipilimumab.
ICOS is a T cell surface molecule structurally related
to CD28 and CTLA-4 [41]. It is expressed at low levels
on resting naïve T cells and is rapidly up-regulated fol-
lowing TCR ligation and CD28 costimulation [42]. After
ipilimumab treatment, ICOS was increased significantlyon CD4+ and CD8+ T cells in both 3-month and 6-
month post-treatment PBMCs (p ≤ 0.0001 with a median
fold-increase of 1.34 to 2.90), with higher increases on
CD4+ than on CD8+ T cells and higher absolute
increases at 3-month than at 6-month post-treatment
(Table 3a and 3b).
Decreased CCR7 on CD8+ and CD4+ T cells after
ipilimumab
The % of CCR7+/CD8+ T cells was decreased at 3-month
post-ipilimumab (p ≤ 0.018 with a median fold-decrease of
0.14, Table 3a). Similarly, the % of CCR7+/CD4+ T cells
was down-regulated at 6-month post-ipilimumab treat-
ment (p ≤ 0.006 with a median fold-decrease of 0.03,
Table 3b).
Table 3 Flow cytometry data for different phenotypic biomarkers from CD4 or CD8 T cells with absolute changes and
fold-changes over baseline control samples at 3- (Table 3a) and 6-month (Table 3b) post ipilimumab with p-values for
the differences shown
Biomarker n Median change * (Q1, Q3) Wilcoxon p-value Median foldchange * (Q1, Q3) Wilcoxon p-value
a. Statistical analysis of changes in biomarkers at 3 months
%-ICOS-CD4 25 13.00 (1.15, 20.69) <.0001 1.35 (0.23, 3.62) <.0001
%-ICOS-CD8 25 4.19 (2.07, 7.75) <.0001 2.90 (1.25, 6.72) <.0001
%-Ki67-CD4 24 3.62 (0.74, 6.94) <.0001 1.50 (0.18, 2.64) <.0001
%-Ki67-CD8 24 1.49 (−0.10, 4.86) 0.0009 0.54 (−0.03, 2.20) 0.0003
%-CCR7-CD8 25 −3.98 (−11.40, 1.30) 0.0122 −0.14 (−0.27, 0.04) 0.018
%-CD25-CD8 25 −1.60 (−5.68, -0.70) <.0001 −0.42 (−0.56, -0.25) <.0001
b. Statistical analysis of changes in biomarkers at 6 months
%-ICOS-CD4 37 9.45 (3.13, 14.57) <.0001 1.66 (0.70, 2.42) <.0001
%-ICOS-CD8 37 3.07 (1.62, 5.36) <.0001 1.34 (0.63, 3.30) <.0001
%-Ki67-CD4 35 2.33 (1.37, 6.97) <.0001 0.87 (0.29, 2.12) <.0001
%-Ki67-CD8 36 1.88 (0.13, 4.91) 0.0004 0.55 (0.04, 1.52) <.0001
%-Gata3-CD4 28 3.76 (0.28, 8.04) 0.0004 0.94 (−0.01, 1.62) <.0001
%-Gata3-CD8 28 2.07 (0.59, 4.02) 0.0006 0.59 (0.09, 1.23) <.0001
%-CCR7-CD4 37 −2.90 (−6.80, -0.40) 0.0017 −0.03 (−0.09, -0.01) 0.006
*(Q1, Q3) are first and third interquartiles.
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CD25 is a T cell activation marker, the % of CD25 ex-
pression on CD8+ T cells were decreased at 3-month
post-ipilimumab (p ≤ 0.0001 with a median fold-decrease
of 0.42, Table 3a).
Increased GATA3 expression in CD4+ and CD8+ T cells
GATA3 is a transcription factor that is a marker for Th2
polarization and is associated with the generation of Th2
cytokines IL-4, IL-5 and IL-10. After treatment with ipi-
limumab, GATA3 expression was increased significantly
in CD4+ and CD8+ T cells at 6-month post-ipilimumab
treatment (p ≤ 0.0006 with a median fold-increase of
0.94 and 0.59, Table 3b).Table 4 Association of phenotypic changes on T cells with cli
vs. No) (Table 4b) was based on univariable logistic regressio
Biomarker n Slope
a. Association of changes in biomarkers at 6 months with outcome (Relapse
%-Ki67 + EOMES + CD4+ 19 −3.5232
%-CCR7 + CD8+ 37 −0.0947
%-EOMES + CD8+ 36 0.1758
% EOMES + GranzymeB + CD8+ 19 0.2774
b. Association of changes in biomarkers at 6 months with irAE (Yes vs. No)
%-Ki67 + CD8+ 36 −0.3167
A total of 37 paired specimens of PBMC prior to and after four doses of ipilimumab
extracellularly, EOMES, granzyme B and Ki67 were stained intracellularly per MateriaSurrogate biomarkers on/in T cells associated with
relapse or irAE
In an univariable logistic regression analysis using changes in
expression by flow cytometry as a continuous variable one at
a time, only absolute decreases in % of Ki67+EOMES+CD4+
and % of CCR7+CD8+, and increases in % of EOMES+CD8+
and % of GranzymeB+ EOMES+CD8+ Tcells were associated
with a higher odds of relapse with p < 0.04 (OR for incre-
ment of half the interquartile range of the corresponding
change ranging from 0.17 to 0.50 for the negative association
and from 2.63 to 5.00 for the positive association, Table 4a).
Only absolute decrease in % of Ki67+CD8+ T cells was asso-
ciated with a development of irAE with p = 0.02 (OR= 0.47,
Table 4b).nical outcome (Relapse vs. NED) (Table 4a) and irAE (Yes
n modeling
p-value ½ IQR OR (95% CI)
vs. NED)
0.0285 0.5 0.17 ( 0.04, 0.83)
0.0379 7.4 0.50 ( 0.26 0.96)
0.0072 5.5 2.63 ( 1.30, 5.32)
0.0293 5.8 5.00 ( 1.18, 21.23)
0.0217 2.4 0.47 ( 0.24, 0.89)
were analyzed by flow cytometry for the indicated markers. CCR7 was stained
ls and Methods.
Table 5 a, Association between outcome (Relapse vs. NED) and dichotomized biomarkers at baseline. b, Association of
baseline dichotomized biomarkers with irAE (Yes vs. No) for a total 55 patients
Biomarker Outcome n (%) Odds Ratio Fisher
(95% CI) p-value
a. Association between outcome (Relapse/NED) and dichotomized baseline biomarkers by median
%-Ki67 + EOMES + CD8+ (n = 39) 11.25 ( 2.52, 50.27) 0.0012
<=2.11 Relapse 15 ( 75.0)
<=2.11 NED 5 ( 25.0)
>2.11 Relapse 4 ( 21.1)
>2.11 NED 15 ( 78.9)
%-EOMES + CD8+ (n = 54) 3.77 ( 1.16, 12.27) 0.0473
<=55.6 Relapse 14 ( 51.9)
<=55.6 NED 13 ( 48.1)
>55.6 Relapse 6 ( 22.2)
>55.6 NED 21 ( 77.8)
b. Association between irAE (Yes/No) and dichotomized baseline biomarkers by median
%-Ki67 + EOMES + CD4+ (n = 39) 8.00 ( 1.74, 36.70) 0.0079
<=0.446 Yes 12 ( 60.0)
<=0.446 No 8 ( 40.0)
>0.446 Yes 3 ( 15.8)
>0.446 No 16 ( 84.2)
Ki67 and EOMES that was stained intracellularly in a total of 36 paired specimens of PBMC prior to and after four doses of ipilimumab was analyzed by flow
cytometry.
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outcome and irAE
An analysis of biomarkers at baseline dichotomized by
their medians revealed that a low % of Ki67+EOMES+
CD8+ T cells, and a low % of EOMES+CD8+ T cells were
significantly associated with relapse (p =0.001, and 0.047
with OR = 11.25, and 3.77, respectively; Table 5a). These
pre-treatment biomarkers were also confirmed in a uni-
variate logistic regression analysis to be associated with re-
lapse (data not shown). A similar analysis of dichotomized
baseline biomarkers by their medians showed that a low %
of Ki67+EOMES+CD4+ T cells was associated with occur-
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Figure 1 a: Kaplan-Meier relapse-free survival curves comparing patie
to patients with (low) less than median % of EOMES+CD8+. b, Kaplan-M
baseline % of Ki67+EOMES+/CD8+ to patients with low % of Ki67+EOMES+/Pre-treatment biomarkers on/in T cells associated with
RFS
Our analysis highlighted the potential importance of
EOMES, a transcription factor in the T-box family and
involved in the regulation of INF-γ, granzyme B and per-
forin production by CD8+ T cells [43]. To better under-
stand the potential role of EOMES+CD8+ T cells in
ipilimumab treatment, we stratified pre-treatment speci-
mens by the median % of EOMES+CD8+ T cells. Patients
with higher baseline % of EOMES+CD8+ T cells had a sig-
nificantly improved relapse-free survival (RFS) compared
to those with a lower basal level of EOMES+CD8+ T cells
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Patients with a higher proportion of Ki67+EOMES+CD8+ T
cells had significantly improved RFS compared with those
with a lower % of Ki67+EOMES+CD8+ T cells (p = 0.0004,
Figure 1b).
We also assessed these biomarkers in 11 pheresis spe-
cimens from normal donors as a reference. Levels of the
most significant biomarker-% of EOMES+Ki67+CD8+ T
cells from the 11 normals and the 55 melanoma patients
in this trial are presented in Additional file 1: Figure S2.
The median % of EOMES+Ki67+CD8+ T cells for the 11
normals was 1.57, very similar to the median of 1.50 for
the relapsed patients (Wilcoxon Rank-sum test p = 0.38).
For the NED group, the median % of EOMES+Ki67+CD8+
T cells was 2.50, significantly higher than that of relapsed
patients (p = 0.003) as well as that of the normal patient
specimen (p = 0.026).
Discussion
In the current study, we utilized an expression micro-
array analysis of flow cytometry-purified CD4+ and CD8
+ T cells to define immunologically important gene pro-
ducts expressed by T cells from patients with high-risk
melanoma that were significantly altered after ipilimu-
mab. We then investigated selected T cell markers by
performing flow cytometry analysis of membrane-bound
and intra-cellular determinants using a larger group of
samples, including 25 sets of pre-, 3-month, and 37 sets
of pre- and 6-month post-treatment PBMCs and 55 pre-
treatment PBMC samples. We aimed to define potential
biomarkers for ipilimumab treatment and determine if
they were associated with clinical outcome and induc-
tion of irAE. The patients’ age, gender, disease stage and
the dosage of ipilimumab (3 vs. 10 mg/kg) were not sig-
nificantly associated with either outcome or irAE, nor
did they significantly impact on the studied biomarkers
(data not shown).
Previous investigations have focused on observations
in peripheral blood or tumors from patients who have
received CTLA-4 antibodies. CTLA-4 abrogation is
expected to result in diffuse CD4+ and CD8+ T cell ex-
pansion and activation, based on the extensive lymphoid
hypertrophy seen in the CTLA-4−/− knockout mice,
and on the rise in ALC commonly observed in patients
receiving ipilimumab. Several investigators described
increases in CD4+HLA-DR+ activated T cells, reductions
in naïve T cells and an increase in central memory cells
in those patients. In the current study, we also observed
similar changes (data not shown). Augmented Th17 cells
and increases in CD4+ICOS+ cells have also been
described after CTLA-4 blockade, however no detailed
analysis has explored the effects of CTLA-4 blocking
antibodies on the expression of different immune mar-
kers on T cells.In the current work, a number of biomarkers on
and in T cells were significantly elevated after repeated
injections of ipilimumab. Increased ICOS on CD4+ and
CD8+ T cells was a pharmacodynamic marker for ipili-
mumab treatment, confirming results from prior studies.
Increased CD4+ICOSHi T cells have been reported to in-
filtrate tumor tissues and are found in peripheral blood
after ipilimumab. In a small number of patients, a signifi-
cant increase of CD4+ICOSHi and CD8+ICOSHi T cells
was observed at weeks 3 and 7. By week 24, CD4+ICOSHi
T cells had returned to baseline values. Increased ICOS
on CD4+ T cells was more pronounced after treatment
with ipilimumab at 10 mg/kg/dose, with concomitant
increases in CD8+ICOSHi T cells which were not
observed after treatment with the 3 mg/kg/dose of anti-
body. In that small study, a sustained increase in fre-
quency of CD4+ICOSHi T cells was associated with
overall survival at week 24 [27]. Our current study is
consistent with a significant increase of ICOS expres-
sion on both CD4+ and CD8+ T cells not only at 3- but
also at 6- months (24 weeks) post ipilimumab independ-
ent of age, sex, metastatic stage of disease, or dose of
ipilimumab. Changes in ICOS expression on CD4 or
CD8 T cells were not associated with clinical outcome
in our analysis. ICOS is not necessary for Th17 differen-
tiation, but it is required for the expansion of the Th17
compartment [44]. ICOS expressing cells may also dem-
onstrate anti-tumor reactivity and be responsible in part
for the anti-tumor effects of ipilimumab [45].
We observed that ipilimumab resulted in consistently
elevated Ki-67, a nuclear proliferation marker, in both
CD4+ and CD8+ T cells 3- and 6- month post ipilimu-
mab. Interestingly, there was no alteration observed in
the frequency of Ki67 positive cells among tumor infil-
trating lymphocytes when post –tremelimumab biopsies
were compared to baseline biopsies [34]. The reason for
increased Ki-67 in CD4+ and CD8+ T cells in peripheral
blood, but not in the tumor site might be due to the dif-
ferences in the CTLA-4 blocking antibodies or the
different time points for sample harvesting, or lympho-
cytes may proliferate in lymphoid organs [33] and the
peripheral blood compartment before they infiltrate
into tumor sites.
The activation marker ICOS, proliferation marker
Ki67, and the Th2 polarizing transcription factor GATA3
were also elevated on CD4+ and CD8+ T cells, suggesting
that prolonged CTLA-4 blockade induced the general-
ized expansion of activated T cells that might generate
Th2 cytokines IL-4, IL-5 and IL-10. Elevated levels of T
cell IFN-γ were detected on the microarray analysis, in
contradistinction to the increase in GATA3. The obser-
vation that CCR7 was decreased on CD8+ and CD4+ T
cells was consistent with the diminution of naïve T cells
in the circulation.
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iety of immune markers either rose or declined on CD4+
and CD8+ T cells after treatment with ipilimumab. The
microarray data defined a larger group of altered genes
that increased by at least 1.2 fold or decreased by 0.8 fold
in the CD4+ cells than in CD8+ T cells, suggesting that
effects of CTLA-4 blockade with ipilimumab were pre-
dominantly on the CD4+ T cell population. CTLA-4 sig-
nals block the lymphocyte cell cycle at the G1 to S
transition. Ipilimumab released the cell cycle arrest of
CD4+ and CD8+ T cells, as demonstrated by the significant
alteration of a group of cell cycle genes (data not shown).
Our data are consistent with other studies showing
that the effects of CTLA-4 blockade are more prominent
on CD4+ T cells, and that T lymphocytes are broadly
expanded. Our data on the association of relapse with
phenotypic changes on CD8+ T cells are novel and point
to the importance of this cell population in the mechan-
ism of ipilimumab’s anti-tumor effect. The use of micro-
arrays and T cell phenotypic analysis to confirm the
changes in gene expression would not have detected the
alterations seen in detailed phosphoflow assays by
Comin-Anduix et al [32]. Interestingly, the microarray
analysis in the current work did not show that major
alterations were seen in downstream TCR and cytokine
signaling molecules, so we cannot confirm or refute
their data. We did not see significant changes in FoxP3
or GITR expression, consistent with our own and others’
work, nor were cytokine levels appreciably altered other
than gamma interferon. While we focused on the effects
of ipilimumab on T cells as an effective immunothera-
peutic agent, it might also have a wider impact on the
immune system, not only on CD4+ and CD8+ T cells as
in our current study, but also on CD14+ monocytes [32]
and B cells [46].
Ipilimumab may also rescue tumor-impaired IFN-γ
pathways in CD4+ T cells [47], since a number of genes
associated with IFN-γ signals such as STAT1, ISG15,
GBp1, and EIF2AK2 were up-regulated by ipilimumab
(data not shown). Up-regulation of STAT1 has been
confirmed by phosphoflow [32] after tremelimumab.
Eomesodermin (EOMES) is an important transcription
factor controlling the function of effector CD8+ T cells
[43]. The expression of EOMES in CD8+ T cells may re-
flect a critical basal level of immune competence of the
melanoma patient. CD8+ T cells play a vital role in the
immune response to melanoma, and their baseline level
of activation and function may be a sine qua non for the
therapeutic effect of ipilimumab. CTLA-4 signaling may
specifically target EOMES resulting in reduced IFN-γ
and granzyme B expression by selectively inhibiting ac-
cumulation of EOMES mRNA and protein [48]. Ectopic
expression of EOMES reversed CTLA-4 mediated inhib-
ition of effector molecules, and CTLA-4-/ CD8+ T cellshad greatly enhanced IFN-γ and granzyme B production,
as well as enhanced cytolytic function and increased ex-
pression of EOMES [48]. The increase in IFN-γ signals
and up-regulated % of granzyme B expression on
EOMES+/CD8+ T cells (p = 0.003, data not shown) in
our current study would suggest ipilimumab interferes with
the down-regulation of EOMES and its downstream sig-
nals, IFN-γ and granzyme B, that is mediated by CTLA-4
engagement. The pre-treatment expression of EOMES in
CD8+ T cells and the level of Ki67+EOMES+CD8+ T cells
are indices that appear to be associated with decreased risk
of relapse and prolonged RFS after adjuvant treatment with
ipilimumab, and these biomarkers could potentially be pre-
dictive for its benefit.
How do these data inform us about the effects of
CTLA-4 abrogation in patients? First, the pharmacody-
namic effects of ipilimumab in vivo can help clarify its
mechanism(s) of action. Next, some of the observed
effects may be surrogate biomarkers for either toxicity
or benefit, allowing an early prediction of those phenom-
ena in patients. Some biomarkers on CD8+ T cells were
associated with relapse in this study, and that result
needs to be validated in a larger prospective study of
patients with metastatic, unresectable melanoma. Our
microarray data also indicated that other genes whose
expression is altered in CD4 and CD8 T cells after ipili-
mumab might be worth exploring. Finally, some of the
biomarkers that we defined herein may be predictive for
the effects of ipilimumab in patients, allowing better pa-
tient selection, or may simply be prognostic for outcome
independent of specific treatment. We showed that
EOMES+CD8+ T cells and Ki67+EOMES+CD8+ T cells
are biomarkers associated with clinical outcome with ipi-
limumab. Further studies to validate these observations
prospectively may define clinically useful predictive bio-
markers to select patients for ipilimumab treatment.Additional file
Additional file 1: Supplementary Tables and Figures. Table S1a:
Demographic data for the 12 patients for which microarray data are
shown in Table 2. Table S1b: Demographic data for the 25 patients for
which flow cytometry data are shown in Table 3a. Table S1c:
Characteristics of 37 patients for which flow cytometry data are shown in
Table 3b and Table 4. Figure S1: Gating strategy and representative
biomarkers in the study. Additional file 1: Figure S2: Box plot illustrates
the % of EOMES + Ki67 + CD8+ T cells in normal donors, relapsed and NED
melanoma patients in the trial. Whiskers in box plots indicate maximum
and minimum values measured. Cross indicates the mean, while line
indicates the median. P-values in the graph are from Wilcoxon rank-sum
test. Overall p-value = 0.038 for comparing the three groups from Kruskal-
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